News

PMD Informs About the Record Date and Procedure of Reverse Split of Shares

STOCKHOLM, SWEDEN / ACCESSWIRE / January 25, 2024 / PMD Device Solutions (STO:PROMO)(FRA:8T0) At PMD's General Meeting on December 29,…

2 months ago

Castellum Announces Pricing of $2.7 Million Registered Direct Offering

Castellum Announces Pricing of $2.7 Million Registered Direct Offering Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and…

2 months ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…

2 months ago

Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.

Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase…

2 months ago

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…

2 months ago

NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program

Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturingDURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE)…

2 months ago

Intelligent Bio Solutions Inc. Announces Reverse Stock Split

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical…

2 months ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration…

2 months ago

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 months ago

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on…

2 months ago